公开(公告)号：US20190233426A1

公开(公告)日：2019-08-01

申请号：US16311575

申请日：2017-06-09

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: C07D487/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.

公开(公告)号：US20190202828A1

公开(公告)日：2019-07-04

申请号：US16311621

申请日：2017-06-06

Applicant: Novartis AG

Inventor： Ho Man CHAN ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying HUANG ,  Ling LI ,  Yuan MI ,  Wei QI ,  Martin SENDZIK ,  Yongfeng SUN ,  Long WANG ,  Zhengtian YU ,  Hailong ZHANG ,  Ji Yue ZHANG ,  Man ZHANG ,  Qiong ZHANG ,  Kehao ZHAO

IPC: C07D471/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

公开(公告)号：US10689378B2

公开(公告)日：2020-06-23

申请号：US16311621

申请日：2017-06-06

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: C07D471/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.

公开(公告)号：US10676479B2

公开(公告)日：2020-06-09

申请号：US16311575

申请日：2017-06-09

Applicant: Novartis AG

Inventor： Ho Man Chan ,  Xingnian Fu ,  Xiang-Ju Justin Gu ,  Ying Huang ,  Ling Li ,  Yuan Mi ,  Wei Qi ,  Martin Sendzik ,  Yongfeng Sun ,  Long Wang ,  Zhengtian Yu ,  Hailong Zhang ,  Ji Yue Zhang ,  Man Zhang ,  Qiong Zhang ,  Kehao Zhao

IPC: C07D487/04 ,  A61P35/00

Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.